Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells. Editorial Article uri icon

Overview

abstract

  • Chimeric antigen receptor T (CAR-T) cells directed against CD19 have transformed the therapy of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). A recent study reports promising activity and safety of CD19 CAR-T cells generated from naïve, stem, and central memory T cells in adults with R/R B-ALL. See related article by Aldoss et al., p. 742.

publication date

  • February 16, 2023

Research

keywords

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Receptors, Chimeric Antigen

Identity

PubMed Central ID

  • PMC9957814

Scopus Document Identifier

  • 85148249895

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-22-3232

PubMed ID

  • 36507801

Additional Document Info

volume

  • 29

issue

  • 4